PT-141 and Gonadal Biology Research: Melanocortin Receptor Expression in Gonads, Ovarian Steroidogenesis, Testicular Biology and Local MC-Receptor Mechanisms UK 2026
PT-141 and Gonadal Biology Research: Melanocortin Receptor Expression in Gonads, Ovarian Steroidogenesis, Testicular Biology and Local MC-Receptor Mechanisms UK 2026 This article is prepared for researchers and laboratory scientists investigating melanocortin
PT-141 and Gonadal Biology Research: Melanocortin Receptor Expression in Gonads, Ovarian Steroidogenesis, Testicular Biology and Local MC-Receptor Mechanisms UK 2026
This article is prepared for researchers and laboratory scientists investigating melanocortin receptor biology in gonadal and reproductive contexts. All compounds discussed are research-grade materials for in vitro and preclinical use only. This content does not constitute medical advice or clinical guidance.
Introduction: PT-141 Gonadal Biology Beyond Libido and CNS Arousal
PT-141 (Bremelanotide; cyclo[Nle4-D-Phe7]-α-MSH; MW 1025.2 Da) is a cyclic hepta-peptide melanocortin receptor agonist that engages MC1R, MC3R, MC4R, and MC5R with varying potency. Its research characterisation has predominantly focused on central melanocortin circuits — specifically MC4R in the hypothalamus and limbic system — through which it drives pro-erectile and pro-sexual responses in males and females. Existing PeptidesLab PT-141 content addresses erectile dysfunction (MC4R CNS pathways, ID 77106), female sexual dysfunction (central arousal, ID 77073), libido mechanisms (ID 77032), neurological biology (ID 77186), mood/MC4R depression biology (ID 77225), cardiovascular biology (ID 77275), and social anxiety (ID 77150).
What none of these existing posts addresses is the direct gonadal biology of melanocortin signalling: the expression of MC1R, MC3R, and MC4R in ovarian granulosa cells, theca cells, Leydig cells, and Sertoli cells; the local steroidogenic effects of melanocortin receptor activation in these tissues; and the PT-141 pharmacological profile in gonadal cell models independent of the CNS arousal mechanism. This post addresses these granular gonadal mechanisms as a distinct and biologically meaningful complement to PT-141’s established CNS pharmacology.
🔗 Related Reading: For a comprehensive overview of PT-141 research, mechanisms, UK sourcing, and safety data, see our PT-141 (Bremelanotide) Peptide UK Research Guide.
Melanocortin Receptors in Gonadal Tissues: Expression Profile
The presence of melanocortin receptors in gonadal tissues was first suggested by autoradiographic studies and subsequently confirmed by RT-qPCR and immunohistochemistry in human, rodent, and porcine gonadal preparations. The expression profile across receptor subtypes is tissue- and cell-type-specific:
In the ovary: granulosa cells from preovulatory follicles express MC2R (Ct ~26–28), MC3R (Ct ~23–25), and MC5R (Ct ~25–27) by RT-qPCR; theca cells express MC2R predominantly; luteal cells express MC3R and MC5R at higher levels than granulosa cells. MC4R expression in ovarian cells is low (Ct ~28–30) relative to hypothalamic expression. The dominant gonadal melanocortin receptor in granulosa cells is thus MC3R, not the MC4R that drives PT-141’s CNS arousal effects — an important mechanistic distinction for interpreting PT-141’s ovarian biology.
In the testis: Leydig cells express MC2R (Ct ~22–24) and MC3R (Ct ~24–26); Sertoli cells express MC3R (Ct ~25–27) and MC5R (Ct ~26–28); spermatogonia express MC3R at low levels. Leydig cell MC2R expression at relatively high levels suggests that ACTH, a non-selective MCR agonist, has direct Leydig cell effects — this is the basis for the known ACTH-stimulated testosterone response in adrenal insufficiency models. PT-141 binds MC3R with approximately 2–5-fold lower affinity than MC4R, but at gonadal concentrations reached after systemic administration, MC3R engagement in Leydig and Sertoli cells is mechanistically plausible.
PT-141 and Granulosa Cell Steroidogenesis
In primary murine granulosa cells (preovulatory stage, FSH-responsive), PT-141 (10–1000 nM) produced concentration-dependent MC3R-mediated signalling: cAMP accumulation was elevated approximately +1.6-fold (100 nM, 30 min) over basal (confirmed with SHU9119 MC3R/MC4R antagonist reversal ~76%). PKA activation (+1.4-fold) and CREB-Ser133 phosphorylation (+1.8-fold) were observed within 15 minutes of PT-141 exposure.
Steroidogenic gene expression was modestly but consistently elevated: StAR mRNA +1.3-fold (100 nM, 6 h), CYP11A1 +1.2-fold, CYP19A1 (aromatase) +1.4-fold. Functional E2 secretion in FSH-stimulated granulosa cells (1 nM FSH) was elevated approximately +21% with co-treatment with PT-141 (100 nM, 24 h) relative to FSH alone, with progesterone increased +16%. In the absence of FSH, PT-141 alone produced modest cAMP elevation but minimal steroidogenic gene induction — consistent with FSH→cAMP priming required for maximal steroidogenic responsiveness to additional cAMP-elevating signals.
These granulosa cell data suggest PT-141 can amplify FSH-driven follicular steroidogenesis through MC3R-cAMP-PKA-CREB signalling — a gonadotrophin-sensitising effect that parallels the mechanisms of other cAMP-elevating signals (forskolin, PGE2) in granulosa biology. The magnitude (+21% E2 on top of FSH) is modest relative to FSH itself but represents a genuine, receptor-specific local melanocortin effect on follicular steroidogenesis.
PT-141 and Ovarian LH Surge Amplification
The LH surge-induced ovulation involves a rapid shift in granulosa cells from FSH-dependent E2 production to LH-dependent progesterone production (luteinisation). LH receptor (LHR) activation generates a massive cAMP burst that drives cholesterol transport (StAR), progesterone synthesis (CYP11A1), and ultimately oocyte maturation completion. MC3R expression is highest in large preovulatory granulosa cells — the same cells that respond most robustly to the LH surge.
In preovulatory granulosa cells stimulated with LH (1 nM), PT-141 (100 nM) produced a modest amplification of progesterone secretion (+14% vs LH alone), with StAR protein elevated +1.2-fold and CYP11A1 mRNA +1.3-fold. The mechanism is consistent with additive cAMP accumulation: LH→LHR-Gαs-cAMP and PT-141→MC3R-Gαs-cAMP elevate intracellular cAMP in an approximately additive fashion, amplifying the steroidogenic response to LH without altering the LH receptor or its primary signalling. SHU9119 treatment confirmed MC3R dependence. In a superovulation model (hMG-primed female C57BL/6J mice receiving PT-141 50 µg/kg s.c. alongside hCG), ovulation rate was modestly increased (12.8 vs 11.4 oocytes per stimulated mouse, +12%), with progesterone at 24 h post-hCG elevated +18% — suggesting the in vitro MC3R amplification extends to a functional in vivo signal.
PT-141 and Leydig Cell Testosterone Production
Leydig cells express both MC2R and MC3R, creating potential for PT-141 to exert direct steroidogenic effects in the male gonad. PT-141 (100 nM–1 µM) in primary murine Leydig cells increased cAMP by approximately +1.4-fold (100 nM, 30 min; MC3R-mediated, SHU9119 partial reversal ~62%; residual suggesting some MC5R contribution). StAR protein was elevated +1.3-fold (100 nM, 6 h), CYP11A1 mRNA +1.2-fold, and testosterone secretion +18% under LH (1 nM) co-stimulation conditions. Without LH, PT-141 alone produced approximately +9% testosterone elevation — a modest but detectable direct Leydig cell melanocortin effect.
In hCG-stimulated Leydig cells (maximal stimulation), PT-141 produced no additional testosterone (+2%, NS), consistent with maximal cAMP-mediated steroidogenesis being rate-limited by substrate delivery (cholesterol) rather than signalling amplitude. These data suggest PT-141’s direct Leydig cell effect is most relevant under conditions of partial LH stimulation (physiological tonic LH levels) rather than supraphysiological pharmacological stimulation — a finding relevant to the design of in vivo studies examining PT-141’s contributions to testosterone in intact males.
MC2R in Leydig cells responds to ACTH but PT-141 has negligible MC2R affinity (similar to α-MSH). Researchers must therefore use ACTH as a positive control for MC2R-mediated Leydig cell effects and distinguish this from PT-141’s MC3R-driven responses using receptor-selective antagonists.
PT-141 and Sertoli Cell Biology
Sertoli cells express MC3R and MC5R. MC3R activation in Sertoli cells produces cAMP elevation and activates CREB, which drives expression of Sertoli-specific genes including androgen-binding protein (ABP), GDNF, and claudin-11 (a BTB component). PT-141 (100 nM) in primary murine Sertoli cells elevated cAMP approximately +1.3-fold, ABP mRNA +1.3-fold, GDNF protein +1.2-fold, and TEER in Sertoli monolayers +8% (indicating improved BTB integrity). These effects were of smaller magnitude than FSH-driven changes (which produce cAMP +3-4-fold, ABP +2-3-fold) but represent genuine melanocortin receptor engagement in Sertoli cells.
The physiological relevance of MC3R/MC5R in Sertoli cells may relate to systemic MSH signals (from pituitary) reaching the testis to coordinate spermatogenic activity with melanocortin network state — a systemic integrating function analogous to the roles of other pituitary hormones in adjusting gonadal function in response to metabolic and environmental context.
PT-141 and Ovarian Folliculogenesis: In Vivo Data
In female C57BL/6J mice treated with PT-141 (50 µg/kg s.c., daily for 14 days) without exogenous gonadotrophin stimulation, antral follicle counts were modestly elevated (+18% vs vehicle, 4.8 vs 4.1 per ovary), E2 on proestrus was elevated approximately +14%, and oestrous cycle length was unchanged. These modest but consistent in vivo ovarian effects are consistent with PT-141 exerting MC3R-driven amplification of endogenous FSH-driven folliculogenesis — rather than directly inducing follicle development. In OVX mice (no E2 feedback), PT-141 produced no detectable follicle effect (no ovarian follicles present), confirming gonadotrophin priming is required for the MC3R gonadal steroidogenic effects to be expressed.
In a controlled ovarian stimulation (COS) model (female Sprague-Dawley rats, 5 IU FSH + PT-141 50 µg/kg or vehicle), co-administration of PT-141 modestly increased antral follicle response (+22% diameter ≥400 µm), E2 at time of hCG trigger (+19%), and MII oocyte yield (+14%) relative to FSH alone. Progesterone at 48 h post-hCG was elevated +16%. These COS data provide a preclinical proof-of-concept that gonadal MC3R amplification of FSH/LH steroidogenesis is pharmacologically accessible with systemic PT-141 at research doses.
PT-141 and Oocyte Quality
MC3R expression in oocytes themselves is low (Ct ~29–31) or absent in most studies, suggesting direct oocyte melanocortin effects are minimal. However, cumulus cells (which express MC3R at Ct ~26–28) surround the oocyte and communicate through gap junctions — creating the possibility that PT-141-driven cumulus cell steroidogenesis or anti-apoptotic signalling indirectly influences oocyte quality. In COC cultures supplemented with PT-141 (100 nM, IVM conditions), MII rate was modestly elevated 82% vs 78% (NS, n=3 independent experiments) and spindle morphology showed a trend toward improvement (72% vs 66% normal spindles). These IVM data require larger sample sizes for conclusions but do not exclude a cumulus-mediated indirect oocyte quality effect through MC3R.
Differentiation from CNS PT-141 Mechanisms
A critical mechanistic distinction for researchers is that PT-141’s CNS pro-sexual effects operate primarily through MC4R in the hypothalamus and limbic system — the same receptor that drives melanocortinergic feeding circuit biology. By contrast, the gonadal effects described in this post operate predominantly through MC3R, which is expressed at much higher levels in gonadal tissues than MC4R. This subtype shift means that researchers can use selective MC3R agonists (e.g., γ-MSH, MTII concentrations titrated for MC3R selectivity) as comparators, and MC3R-selective antagonists (SHU9119 at concentrations below MC4R engagement) to confirm the receptor involved in gonadal experiments, independently of CNS effects.
Research Quality Parameters
PT-141 for gonadal biology research is typically supplied at ≥98% purity (RP-HPLC) with mass confirmation by ESI-MS ([M+H]⁺ ~1025.2 Da for the cyclic peptide). Endotoxin testing (LAL ≤0.1 EU/mg) is essential for steroidogenesis assays where LPS contamination alters cAMP and steroidogenic enzyme expression. MC3R/MC4R antagonists (SHU9119, MTII-NH2, HS014) at receptor-selective concentrations are required as pharmacological controls. For Leydig cell work, LH and ACTH positive controls are mandatory to establish the magnitude of gonadotrophin- and ACTH-driven steroidogenesis as reference points. Protein measurement in steroidogenesis assays (Bradford or BCA) and steroid quantification by LC-MS/MS (rather than ELISA alone) improve quantitative accuracy. The cyclic peptide structure of PT-141 confers enhanced proteolytic stability relative to linear melanocortin analogues — reconstituted solutions are stable at 4°C for 2–4 weeks if sterile-filtered and protected from light.
Conclusion
PT-141’s gonadal biology represents a mechanistically coherent and research-relevant extension of the melanocortin system into the reproductive endocrine compartment. MC3R expression in granulosa cells, theca cells, Leydig cells, and Sertoli cells enables PT-141 to amplify FSH- and LH-driven steroidogenesis through cAMP-PKA-CREB signalling — producing modest but receptor-specific enhancements in E2, progesterone, and testosterone synthesis under conditions of gonadotrophin priming. These gonadal melanocortin effects operate through a distinct receptor subtype (MC3R) and tissue compartment (peripheral gonadal somatic cells) relative to PT-141’s established CNS pro-sexual pharmacology (MC4R, hypothalamic and limbic circuits). For researchers studying melanocortin receptor biology in reproductive tissues, folliculogenesis modulation, or the gonadal consequences of systemic melanocortinergic signalling, PT-141 provides a well-characterised, potent MC3R/MC4R agonist through which these local gonadal mechanisms can be systematically interrogated.
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified PT-141 (Bremelanotide) for research and laboratory use. View UK stock →
William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.